The global burden of tuberculous meningitis in adults : a modelling study by Dodd, P.J. et al.
This is a repository copy of The global burden of tuberculous meningitis in adults : a 
modelling study.




Dodd, P.J. orcid.org/0000-0001-5825-9347, Osman, M., Cresswell, F.V. et al. (7 more 
authors) (2021) The global burden of tuberculous meningitis in adults : a modelling study. 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
The global burden of tuberculous meningitis
in adults: Amodelling study
Peter J. DoddID
1*, MuhammadOsmanID2, Fiona V. CresswellID3,4,5, Anna M. Stadelman6,




10, Sicelo S. Dlamini11, James A. SeddonID
2,12
1 School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 2 Desmond
Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South
Africa, 3 London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Infectious Diseases
Institute, Kampala, Uganda, 5 MRC-UVRI-LSHTMUganda Research Unit, Entebbe, Uganda, 6 School of
Public Health, University of Minnesota, Minneapolis, MN, United States of America, 7 PhamNgoc Thach
Hospital, Ho Chi Minh City, Vietnam, 8 Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam,
9 Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 10 Tuberculosis Section,
National Infection Service, Public Health England, London, United Kingdom, 11 Research Information
Monitoring, Evaluation, and Surveillance, National Tuberculosis Control and Management Cluster, National
Department of Health, Pretoria, South Africa, 12 Department of Infectious Diseases, Imperial College
London, London, United Kingdom
* p.j.dodd@sheffield.ac.uk
Abstract
Tuberculous meningitis (TBM) is the most lethal form of tuberculosis. The incidence and
mortality of TBM is unknown due to diagnostic challenges and limited disaggregated report-
ing of treated TBM by existing surveillance systems. We aimed to estimate the incidence
and mortality of TBM in adults (15+ years) globally. Using national surveillance data from
Brazil, South Africa, the United Kingdom, the United States of America, and Vietnam, we
estimated the fraction of reported tuberculosis that is TBM, and the case fatality ratios for
treated TBM in each of these countries. We adjusted these estimates according to findings
from a systematic review and meta-analysis and applied them toWorld Health Organization
tuberculosis notifications and estimates to model the global TBM incidence and mortality.
Assuming the case detection ratio (CDR) for TBM was the same as all TB, we estimated
that in 2019, 164,000 (95% UI; 129,000–199,000) adults developed TBM globally; 23%
were among people living with HIV. Almost 60% of incident TBM occurred in males and 20%
were in adults 25–34 years old. 70% of global TBM incidence occurred in Southeast Asia
and Africa. We estimated that 78,200 (95% UI; 52,300–104,000) adults died of TBM in
2019, representing 48% of incident TBM. TBM case fatality in those treated was on average
27%. Sensitivity analysis assuming improved detection of TBM compared to other forms of
TB (CDR odds ratio of 2) reduced estimated global mortality to 54,900 (95% UI; 32,200–
77,700); assuming instead worse detection for TBM (CDR odds ratio of 0.5) increased esti-
mated mortality to 125,000 (95% UI; 88,800–161,000). Our results highlight the need for
improved routine TBMmonitoring, especially in high burden countries. Reducing TBM inci-
dence and mortality will be necessary to achieve the End TB Strategy targets.
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Introduction
Following inhalation of aerosolizedM. tuberculosis, most individuals either eradicate or con-
tain the organism through innate and adaptive immune mechanisms [1]. Failure of these
mechanisms, however, can result in haematogenous dissemination of bacilli to distant sites,
including to the meninges surrounding the brain [1–4]. Once bacilli replicate within the
meninges and cause local inflammation, the clinical condition of tuberculous meningitis
(TBM) results. In the wake of the HIV epidemic, in high tuberculosis prevalence countriesM.
tuberculosis is now the second leading cause of meningitis after Cryptococcus [5, 6]. TBM is
universally fatal if untreated and even when treated is associated with high mortality [7–9].
Amongst survivors, severe permanent disability is common with a substantial cost to individu-
als, families, and society [7, 8]. In addition, the time from symptom onset to death is much
more rapid than for other forms of tuberculosis.
TBM can cause a diverse clinical picture including altered mental status, meningitic fea-
tures, seizures, cranial nerve palsies, and focal neurological deficits [10–12]. Many of these fea-
tures overlap with other conditions [10], and consequently TBMmay not be readily
considered if a patient seeks care. Diagnosing TBM comes with several additional challenges,
which are most acute in low- and middle-income countries (LMICs). First, diagnosis can only
be made using cerebrospinal fluid (CSF), requiring a lumbar puncture [13, 14]. Secondly, once
a sample is obtained, processing requires appropriate laboratory capacity. Finally, even with
the best laboratory infrastructure, the currently available diagnostic tests (smear microscopy,
molecular tests including Xpert MTB/RIF, or CSF culture) are only moderately sensitive and
commonly yield false negative results [15]. These diagnostic obstacles, combined with the
rapid progression to death if untreated mean that many individuals with TBM die undiag-
nosed [16]. Evidence from a high tuberculosis/HIV context found 15% (1348/8759) of menin-
gitis cases had CSF white cells>20/μL with lymphocytic predominance and negative
diagnostic work-up, much of which is likely undiagnosed TBM [17].
Our understanding of the burden of TBM is limited. In addition to the burden of undiag-
nosed TBM, data on those diagnosed with TBM are not routinely captured. Currently, health
programmes report tuberculosis patients as having any pulmonary involvement or being
exclusively extrapulmonary [18], meaning a patient with TBM and pulmonary tuberculosis is
classified as pulmonary tuberculosis. The World Health Organization (WHO) employs model-
ling approaches to estimate the overall burden of incident tuberculosis and tuberculosis deaths
using methods that incorporate notifications, case detection estimates, prevalence surveys,
estimates of case fatality ratios, and vital registration [19]. TBM is not specifically included in
these approaches and a better understanding of TBM burden may influence overall estimates
of global tuberculosis mortality given the high mortality associated with TBM. The Global Bur-
den of Diseases study by the Institute for Health Metrics and Evaluation (IHME) has estimated
the global burden of meningitis and the relative contribution of different causative organisms,
but did not include TBM [20].
Due to underdiagnosis and paucity of population-level data on treated TBM there is sub-
stantial uncertainty about the true incidence, mortality, and societal impact of the disease. A
better understanding the burden of TBM could help the WHO, Ministries of Health, National
Tuberculosis Programmes, and other partner organisations prioritize resources and identify
training needs, and researchers plan future studies. Highlighting the discrepancy between
expected and diagnosed TBM is also an important step in programmatic evaluation, to advo-
cate for programmatic support.
The natural history and clinical manifestations of tuberculosis are different in children and
in adults [21], with young children having a higher risk of progression to disease following
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infection and a higher risk of developing severe, disseminated forms of disease [22]. The pre-
sentation of TBM in young children is less charactersitic than in adults, and the diagnosis is
less commonly confirmed [23]. In addition, Bacillus Calmette–Guérin (BCG) vaccination has
some efficacy against TBM in young children [16], an effect not confirmed in adults. These
factors lead to key epidemiological differences between children and adults in terms of tuber-
culosis and TBM, therefore we chose to focus on adults. In this study we model the global inci-
dence and mortality of adult TBM in different WHO regions, across a range of ages, and by
sex and HIV status.
Methods
Fraction of tuberculosis that is TBM and case fatality ratios
To estimate the proportion of tuberculosis that is TBM (defined by ICD-10 code A17.0), and
their case fatality ratio (CFR) on treatment, we sought national surveillance data that included
counts by year, age, and sex, stratified by HIV status for: notified tuberculosis, notified TBM,
and deaths among notified TBM patients. Data did not always include all categories. We
obtained data for Brazil (19 years, 777,611 tuberculosis patients, 9,267 TBM patients, TBM
deaths unavailable), South Africa (8 years, 2,155,572 tuberculosis patients, 32,362 TBM
patients, 5,067 TBM deaths), United Kingdom (20 years, 139,450 tuberculosis patients, 2,840
TBM patients, TBM deaths unavailable), United States of America (5 years, 44,176 tuberculosis
patients, 676 TBM patients, 183 TBM deaths), and Vietnam (5 years, 62,487 tuberculosis
patients, 3,447 TBM patients, 601 TBM deaths). Most countries used 10-year age categories
from 15 years up to 65+ years. Brazil used different age categories and did not stratify by sex.
United Kingdom data were all from England. Vietnam comprised two data sets: one by year
but without TBM deaths, and another without year not including tuberculosis notifications
(numbers above sum over both datasets). Further information is shown in Table 1.
We used a two-step meta-analysis approach: first conducting country-level meta-analysis
across years (to account for unmeasured random variation between years); second, to pool
country-level estimates. For each country, we used random effects generalized linear meta-
regression (with logit link and Poisson distribution) to estimate the proportion of tuberculosis
incidence that is TBM and the TBM CFRs by age and sex (assuming no sex-age interaction).
Only countries with relevant data were included in each step-two analysis. For Brazil, a
restricted cubic spline meta-regression was used, fitted to the age category mid-points. Predic-
tions and 95% prediction intervals were computed at the midpoints of the common age cate-
gories, and, lacking sex-stratification, these estimates were treated as pertaining to women.
The country-level meta-analytic estimates were then meta-analysed for fractions by age and
sex to produce pooled predictions and I2 used to quantify heterogeneity. For deaths in people
living with HIV (PLHIV), only two countries had data, so an inverse variance-weighted mean
was used for pooling. In South Africa, CFR in PLWHIV was lower than a previous systematic
review and meta-analysis estimates by Stadelman and colleagues [7]. We scaled up the South
African estimates of CFR in PLWHIV so that the weighted average CFR matched the previ-
ously reported value.
Estimates of TBM incidence and mortality
To estimate TBM incidence and mortality in people aged 15 years and over for each country in
2019, stratified by age, sex, and HIV status, we followed the procedure shown in the schematic
in Fig 1. We usedWHO-collated tuberculosis notification data stratified by age and sex, and
WHO estimates of tuberculosis incidence in the corresponding sex and age group. We
assumed that notified tuberculosis patients received treatment, and that the gap between
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Table 1. Number of people included in meta-analysis by characteristic (rows) and type (columns). Percentages of counts within strata are shown in brackets. Blanks
indicate no data.
Stratum Value Tuberculosis TBM TBM deaths
Total Total 3179296 (100%) 48592 (100%) 5851 (100%)
Sex missing 777611 (24%) 9267 (19%)
male 1344697 (42%) 19258 (40%) 3160 (54%)
female 1056988 (33%) 20067 (41%) 2691 (46%)
HIV HIV- 1609560 (51%) 14046 (29%) 855 (15%)
HIV+ 1569736 (49%) 34546 (71%) 4996 (85%)
Country BRA 777611 (24%) 9267 (19%)
GBR 139450 (4%) 2840 (6%)
USA 44176 (1%) 676 (1%) 183 (3%)
VNM 62487 (2%) 1786 (4%)
VNM (deaths) 1661 (3%) 601 (10%)
ZAF 2155572 (68%) 32362 (67%) 5067 (87%)
Age (BRA) 15–19 47236 (6%) 305 (3%)
20–39 381408 (49%) 4668 (50%)
40–59 257834 (33%) 3511 (38%)
60–64 33832 (4%) 328 (4%)
65–69 22960 (3%) 225 (2%)
70–79 25506 (3%) 188 (2%)
80+ 8835 (1%) 42 (0%)
Age (not BRA) 15–24 318274 (13%) 4767 (12%) 443 (8%)
25–34 734746 (31%) 13378 (34%) 1915 (33%)
35–44 645725 (27%) 11556 (29%) 1794 (31%)
45–54 388890 (16%) 5731 (15%) 979 (17%)
55–64 191213 (8%) 2448 (6%) 461 (8%)
65+ 122837 (5%) 1445 (4%) 259 (4%)
Year 2000 6291 (<1%) 69 (<1%)
2001 24676 (1%) 415 (1%)
2002 28109 (1%) 483 (1%)
2003 30352 (1%) 496 (1%)
2004 32058 (1%) 479 (1%)
2005 35761 (1%) 564 (1%)
2006 37189 (1%) 584 (1%)
2007 40511 (1%) 657 (1%)
2008 44464 (1%) 669 (1%)
2009 247192 (8%) 3953 (8%) 514 (9%)
2010 317857 (10%) 5107 (11%) 774 (13%)
2011 357356 (11%) 5464 (11%) 860 (15%)
2012 344327 (11%) 5229 (11%) 772 (13%)
2013 344021 (11%) 5121 (11%) 686 (12%)
2014 363412 (11%) 5303 (11%) 664 (11%)
2015 353144 (11%) 4392 (9%) 411 (7%)
2016 320413 (10%) 4626 (10%) 501 (9%)
2017 84950 (3%) 1193 (2%) 35 (1%)
2018 88307 (3%) 1118 (2%) 33 (1%)
2019 78906 (2%) 1009 (2%)
missing 1661 (3%) 601 (10%)
TBM: tuberculous meningitis; BRA: Brazil; GBR: Great Britain (data all from England); USA: United States of America; VNM: Vietnam; ZAF: South Africa
https://doi.org/10.1371/journal.pgph.0000069.t001
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incidence and notification represented patients who did not receive effective treatment. We
used the WHO estimates of HIV prevalence in incident tuberculosis to stratify tuberculosis
incidence by HIV status and assumed this applied equally to both treated and untreated tuber-
culosis. We then applied our meta-analytic estimates of the fraction of incident tuberculosis
that is TBM by sex and age-group to both treated and untreated incident tuberculosis, there-
fore assuming TBM has the same likelihood of treatment as other forms of tuberculosis. As a
sensitivity analysis, we considered higher and lower odds of detection and treatment for TBM
compared to all tuberculosis, using odds ratios of 2 and 0.5. Finally, we applied our meta-ana-
lytic CFRs for treated TBM to the portion of incidence that received treatment and assumed
that untreated TBM always results in death.
Uncertainty was included for each of the inputs (tuberculosis incidence estimates; propor-
tion of tuberculosis with HIV; meta-analytic proportion of tuberculosis that is TBM; and
CFRs) by analytically propagating variances through calculations to calculate uncertainty
intervals (UI) as 95% quantiles under a normal approximation. We report TBM incidence and
mortality, stratified by age, sex, WHO region, HIV, and tuberculosis treatment status in the
main article, and provide country-level estimates in S1 Appendix. We completed a GATHER
checklist. All analysis was performed in R version 4.0.1; source code and input data are
Fig 1. Flow chart of overall methods. TB: tuberculosis; TBM: tuberculous meningitis; CRF: Case fatality Rate; WHO:World Health Organization.
https://doi.org/10.1371/journal.pgph.0000069.g001
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available at https://github.com/petedodd/tbme. The study was approved by the Stellenbosch
University Health Research Ethics Committee (X20/11/042).
Role of the funding source
The funders of the study had no role in study design, data analysis, data interpretation, or writ-
ing of the report.
Results
Fraction of tuberculosis that is TBM and case fatality ratios
Across all ages and sexes, we estimated between 1.3% and 1.8% for pooled estimates of the pro-
portion of tuberculosis that is TBM in HIV-negative people (Fig 2A; Table 1 in S1 Appendix),
Fig 2. Age, sex, and HIV-stratified fraction of notified tuberculosis that is TB meningitis (top row, A & B), and case fatality ratio among treated TB meningitis
(bottom row, C & D). HIV-negative (first column, A & C); HIV-positive (second column, B & D). Meta-analytic results for each country are shown by solid
points and lines (central estimate) and shaded ribbons (95% confidence intervals). Open points show data for individual years in each country, with size
proportional to denominator count. Pooled meta-analytic estimates are shown as red points, lines and 95% confidence interval error bars. (ISO3 country codes:
ZAF = South Africa, GBR = United Kingdom, USA = United States of America, BRA = Brazil). Brazil has different age categories and no sex disaggregation.
Map data from https://datacatalog.worldbank.org/search/dataset/0038272.
https://doi.org/10.1371/journal.pgph.0000069.g002
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and between 3.6% and 6.8% in PLHIV (Fig 2B; Table 1 in S1 Appendix). Variation between
countries was substantial (country-weighted mean range 0.5% to 2.3%; I2 = 98.6%). Women
consistently showed higher proportions of incident tuberculosis that was TBM, but there were
no clear patterns by age. CFRs increased steeply with age (Fig 2C and 2D) but did not show
clear patterns by sex. The weighted average CFR for HIV-negative individuals was 15.9% (95%
confidence interval [CI]; 13.4% - 18.3%), consistent with the review estimate of 16% (95%CI;
10% - 24%) from Stadelman and colleagues [7]. As noted in the methods, the weighted CFR
for HIV-positive individuals was scaled to match the corresponding review estimate in Stadel-
man and colleagues, i.e. 57% (95%CI; 48% - 67%).
Estimates of TBM incidence and mortality
We estimate that 164,000 (95% UI; 129,000–199,000) adults developed TBM in 2019, of whom
118,000 (95% UI; 85,400–150,000) or 72% were diagnosed and treated (Table 2). Of incident
TBM, 63,200 (95% UI; 35,300–91,000) or 39% were women and 37,800 (95% UI; 19,700–
55,900) or 23% were living with HIV (Table 2). The largest incidence was in the 25-34- and 35-
44-year age groups: 31,900 (95% UI; 18,800–45,000) and 32,700 (95% UI; 19,600–45,900),
respectively. However, all age groups had substantial incidence, including an incidence of
22,400 (95% UI; 12,000–32,900) among those over 65 years (Fig 3). The WHO region with the
greatest burden of incident TBM was the Southeast Asia region with incidence of 65,900 (95%
UI; 34,600–97,100) followed by the African region with incidence of 48,100 (95% UI; 41,400–
54,800).
Our analysis suggests that 78,200 (95% UI; 52,300–104,000) adults died of TBM in 2019
(Table 1). Of the 118,000 individuals with incident TBM that were diagnosed and treated,
31,700 (95% UI; 10,100–53,300) died representing an overall CFR of 27%. All of the 46,500
(95% UI; 32,200–60,900) people with incident TBM that went undiagnosed, were assumed to
die representing 59% of the overall TBM deaths. We estimate that 27,200 (95% UI; 5,280–
49,200) adults with HIV died from TBM representing 35% of all TBM deaths, and we estimate
that of all deaths, 36% (28,300, 95% UI; 18,400–38,300) were women (Table 2). The age group
with the most deaths was the 35–45-year group with 14,900 (95% UI; 9,920–19,900) (Fig 3 and
Table 3). The African and Southeast Asian WHO regions had the most deaths with 30,900
(95% UI; 25,600–36,200) and 26,600 (95% UI; 4,350–48,800) deaths, respectively. Country
level estimates for incidence and mortality are provided in associated repository, and shown
for incidence in Fig 4.
In the primary analysis we assumed that the case detection ratio (CDR) in TBM (the pro-
portion of all estimated TBM that was diagnosed) was the same as the CDR in all tuberculosis
(i.e. the detection odds ratio was 1). Our sensitivity analysis with an odds ratio of 2 (better
detection for TBM) reduced global TBM incidence by 14% to 141,000 (95% UI; 108,000–
174,000) and global TBMmortality by 30% to 54,900 (95% UI; 32,200–77,700) deaths (see
Table 2 in S1 Appendix). Our analysis with worse detection for TBM (odds ratio of 0.5 com-
pared to all tuberculosis) increased global TBM incidence by 29% to 211,000 (95% UI;
168,000–254,000) and global TBMmortality by 60% to 125,000 (95% UI; 88,800–161,000)
deaths (see Table 3 in S1 Appendix).
Discussion
This analysis demonstrated that around 1.5% of HIV-negative tuberculosis patients have
TBM, and that this figure is higher for HIV-positive adults with tuberculosis at around 5%.
The CFR increased with age for both HIV-positive and HIV-negative individuals and was sim-
ilar for men and women. We estimated that 164,000 adults developed TBM worldwide in
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2019, of whom 78,200 died. We found that 23% of the incidence and 35% of deaths were in
HIV-positive individuals and that 72% of all incident TBM are diagnosed and treated each
year. We estimate that 59% of adults that died of TBM were undiagnosed. The burden of inci-
dence and deaths was highest in the younger age groups yet older individuals with treated
TBM had higher CFRs than those younger so contributed relatively more deaths. Compared to
women, men had a higher burden of incidence and deaths for all age groups andWHO
regions, regardless of HIV status.
A previous review article estimated that the global TBM incidence in adults and children
was 100,000/year [4]. The authors justified this estimate through two approaches. First, they
combined the proportion of TBM in a large German cohort of tuberculosis patients (0.9%)
Table 2. Incidence and mortality of tuberculous meningitis, stratified byWHO region, HIV status and whether the patient received TBM treatment.
WHO Region
Metric Treatment HIV AFR AMR EMR EUR SEA WPR Global
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TBM: tuberculous meningitis; AFR: African Region; AMR: Americas Region; EMR: Eastern Mediterranean Region; EUR: European Region: SEA: Southeast Asian
Region: WPR: Western Pacific Region; WHO: World Health Organization
https://doi.org/10.1371/journal.pgph.0000069.t002
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[24] with the global estimate of tuberculosis incidence (10 million/year). Secondly, they used a
Brazilian study which found that 6% of extrapulmonary tuberculosis was TBM [25], and then
applied this first to the proportion of tuberculosis reported to the WHO globally that is extra-
pulmonary (15%) and then to the total WHO estimate of tuberculosis incidence. In the USA,
TBM constituted 1.0% of all incident tuberculosis between 1993 and 2006 [26], however in
Texas this proportion was up to 2.7% [27]. Extrapolating these data directly to tuberculosis
and HIV endemic settings as well as LMICs is problematic as the TBM epidemiology is likely
to be different. Our estimates of TBM incidence and mortality provide insight into the relative
contribution of age, sex, HIV status, and geographic location. In addition, they indicate what
proportion of TBM is diagnosed and treated. Given that our estimates do not include children,
Fig 3. TBM incidence and deaths sex, age, WHO region, HIV-infection and anti-tuberculosis treatment status. TBM: tuberculous meningitis; AFR: African Region;
AMR: Americas Region; EMR: EasternMediterranean Region; EUR: European Region: SEA: South East Asian Region: WPR: Western Pacific Region; WHO:World
Health Organization; F: female; M: male.
https://doi.org/10.1371/journal.pgph.0000069.g003
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who are a high-risk group for TBM, we believe that the overall burden of TBM is substantially
higher than the 100,000/year previously estimated.
The implications of our estimates need careful consideration. TBM is the most severe form
of tuberculosis and contributes to substantial mortality. WHO estimates that 1.4 million indi-
viduals die of tuberculosis each year and our mortality estimates would suggest that 5.6% of
tuberculosis deaths are caused by TBM. We also estimate that just under half of adults who
develop TBM die, a mortality rate far higher than other forms of tuberculosis. Beyond mortal-
ity, TBM can place a substantial strain upon individuals, their families, and societies with pro-
tracted hospitalisation and half of survivors having long-term neurocognitive disabilities
which impair their abilities to work, communicate and function in society [7, 9]. Many require
long-term care from either family members, the healthcare system, or social services, at sub-
stantial cost to society. Access to rehabilitation is often limited in the populations most affected
by tuberculosis. To reduce the burden of mortality, morbidity, and catastrophic costs to
Table 3. Incidence and mortality of tuberculous meningitis, stratified by age band, HIV status and sex.
Age bands (years)
Metric Sex HIV 15–24 25–34 35–44 45–54 55–64 65+ Total
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families the entire programmatic cascade needs to be evaluated and interventions targeted
towards preventing TBM, diagnosing TBM earlier and supporting diagnosed patients with
optimal therapy [28]. There also needs to be increased investment in research to identify new
vaccines, diagnostics, and therapeutics, including both antimicrobials that effectively penetrate
the CSF and host directed therapies to reduce the damage caused by the inflammatory
response. A critical next step would be to fully cost the impact of TBMmortality and morbidity
as any evaluation of novel diagnostics, therapeutics or vaccination should include the cost of
failure to appropriately prevent, diagnose, and treat TBM.
The global epidemiology of adult TBM has commonalities and differences with that of all
tuberculosis. HIV infection is a key risk factor for TBM and although only 8.2% of all tubercu-
losis patients globally are living with HIV, we find that 23% of TBM patients are HIV-positive
[29]. Of the 1.4 million individuals who die each year of tuberculosis, 17% were HIV-positive.
However, we estimate that 35% of the adults who die of TBM each year were HIV-positive.
HIV also impacts the global geography of TBM. While the WHO Africa region contributes
25% of all tuberculosis incidence, it comprises 30% of TBM incidence and 38% of all TBM
deaths. The age and sex distribution of TBM in our estimates largely corresponds to the
known distribution of all tuberculosis: young adults are at high risk, with consistently higher
risk among men in all age groups [30]. The age distribution of TBM deaths is slightly older
than TBM incidence reflecting increasing fatality in treated TBM with age.
We carefully considered the strengths and limitations of several strategies to inform the
best approach. High quality surveillance data are unavailable for most countries and so it was
not possible to use routine data to directly quantify treated TBM incidence or mortality. Many
settings endemic for tuberculosis do not use ICD codes to categorise hospital admissions,
therefore capturing data on TBM survivors from hospital data was not possible. We were
unable to use vital registration data as due to the diverse presentations, difficulties in making a
confirmed diagnosis, and scarcity of autopsies and verbal autopsies, a substantial portion of
TBM goes unrecognised or is misclassified as another neurological illness. Likewise, there
were limited clinical or laboratory data on the TBM fraction in general meningitis cohorts,
Fig 4. Absolute (dot size) and per capita incidence (colour) of TBM by country.
https://doi.org/10.1371/journal.pgph.0000069.g004
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which tended to focus on either acute epidemic meningitis or HIV-associated meningitis. It
was also not possible to use a natural history approach to estimate burden, as has been done
for HIV-associated Cryptococcal meningitis, as TBM can present in both people living with
HIV (at any CD4 count) and immunocompetent hosts, and also at any age; data to inform nat-
ural history parameters in all patient populations is lacking [31]. We therefore chose to use a
method that took as its starting point both the estimated and reported tuberculosis incidence
for each country, stratified by age, sex, and HIV status and used a meta-analysis of several data
sources to estimate the proportion of tuberculosis that is TBM. We assumed the same CDR for
TBM as for all tuberculosis and then applied meta-analytic CFRs, calculated using additional
data sources and from the literature.
Our study has several limitations. To inform our estimate of the proportion of tuberculosis
that is TBM, we obtained data from sources in which data were stratified by age, sex, and HIV
status. However, these data sources used different study designs and employed varying inclu-
sion criteria and definitions of TBM. Also, we used these relationships to model the proportion
in all countries and it is likely that this relationship varies with multiple factors including
tuberculosis prevalence, population demographics, genetics and comorbidities, as well as
health system strength. We also assumed that the proportion of tuberculosis that was TBM
was the same for diagnosed and undiagnosed tuberculosis. We found no data to inform the
magnitude or even direction of the difference between the CDR for TBM and the all-tubercu-
losis CDR, and so assumed this difference was zero in our primary analysis. We undertook a
sensitivity analysis in which we explored the impact of increasing or decreasing the CDR for
TBM. Our modelling of CFR in treated TBM was drawn from several studies that stratified
case fatality by age, sex and HIV status. The South African and US data were from the routine
treatment register and the Vietnam data were from national referral hospital data and clinical
trials. We then adjusted these values using data from a systematic review of published studies.
None of these data sources are truly representative of the CFR experienced by treated TBM in
all global settings. A strength of our work is its independence from vital registration data,
which may be of poor quality in some settings.
These estimates suggest that there is a substantial burden of incident TBM and TBMmor-
tality in adults. Over half of adults who die from TBM die undiagnosed, suggesting that to
make any form of impact on TBMmortality, increasing access to high-quality diagnostics is
required. A substantial proportion of TBM and TBMmortality is HIV-associated so increased
HIV testing, improved access to antiretroviral therapy and retention in HIV care would likely
reduce TBM risk. We believe that there is a strong rationale for countries to collect routine
data on TBM and for more research studies quantifying the long-term neurological deficit in
survivors and the cost to societies. There is also a rationale for including an estimate of TBM
incidence and mortality in both global estimates of tuberculosis and estimates of meningitis to
allow appropriate resource allocation, planning and programme monitoring. Although invest-
ment in TBM prevention, diagnostics, and therapeutics are required, many high tuberculosis-
burden settings also need improved rehabilitation services. Interventions to reduce the inci-
dence of TBM, and to improve TBM outcomes, are likely to be vital if the ambitious WHO
End TB target of reducing tuberculosis deaths by 95% by 2035 are to be met.
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treatment and improved outcome following guideline revision promoting prompt lumbar puncture. Clin
Infect Dis. 2015; 60: 1162–1169. https://doi.org/10.1093/cid/civ011 PMID: 25663160
14. Richie MB, Josephson SA. A Practical Approach to Meningitis and Encephalitis. Semin Neurol. 2015;
35: 611–620. https://doi.org/10.1055/s-0035-1564686 PMID: 26595861
15. Bahr NC, Meintjes G, Boulware DR. Inadequate diagnostics: the case to move beyond the bacilli for
detection of meningitis due to Mycobacterium tuberculosis. J Med Microbiol. 2019; 68: 755–760. https://
doi.org/10.1099/jmm.0.000975 PMID: 30994435
16. Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC, Tuberculous Meningitis International
Research Consortium. The current global situation for tuberculous meningitis: epidemiology, diagnos-
tics, treatment and outcomes.WellcomeOpen Res. 2019; 4: 167. https://doi.org/10.12688/
wellcomeopenres.15535.1 PMID: 32118118
17. Tenforde MW, Mokomane M, Leeme T, Tlhako N, Tsholo K, Ramodimoosi C, et al. Epidemiology of
adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana
national meningitis survey. J Infect. 2019; 79: 212–219. https://doi.org/10.1016/j.jinf.2019.06.013
PMID: 31255634
18. World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision
(updated December 2014 and January 2020). World Health Organization; 2013. Available: https://
apps.who.int/iris/bitstream/handle/10665/79199/9789246505340_ara.pdf
19. Glaziou P, Dodd PJ, Dean A, Floyd K. Methods used byWHO to estimate the global burden of TB dis-
ease. 2020. Available: https://www.who.int/tb/publications/global_report/TB20_Technical_Appendix_
20201014.pdf?ua=1
20. GBD 2016 Meningitis Collaborators. Global, regional, and national burden of meningitis, 1990–2016: a
systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17: 1061–1082.
https://doi.org/10.1016/S1474-4422(18)30387-9 PMID: 30507391
21. Garg RK. Tuberculous meningitis. Acta Neurol Scand. 2010; 122: 75–90. https://doi.org/10.1111/j.
1600-0404.2009.01316.x PMID: 20055767
22. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Nelson LJ, et al. The clinical epidemiology
of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J
Tuberc Lung Dis. 2004; 8: 278–285. PMID: 15139465
23. Garg RK, Sinha MK. Tuberculousmeningitis in patients infected with human immunodeficiency virus. J
Neurol. 2011; 258: 3–13. https://doi.org/10.1007/s00415-010-5744-8 PMID: 20848123
24. Ducomble T, Tolksdorf K, Karagiannis I, Hauer B, Brodhun B, HaasW, et al. The burden of extrapul-
monary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to
2009. Euro Surveill. 2013; 18. Available: https://www.ncbi.nlm.nih.gov/pubmed/23557944 PMID:
23557944
25. Gomes T, Reis-Santos B, Bertolde A, Johnson JL, Riley LW, Maciel EL. Epidemiology of extrapulmon-
ary tuberculosis in Brazil: a hierarchical model. BMC Infect Dis. 2014; 14: 9. https://doi.org/10.1186/
1471-2334-14-9 PMID: 24400848
26. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tubercu-
losis in the United States, 1993–2006. Clin Infect Dis. 2009; 49: 1350–1357. https://doi.org/10.1086/
605559 PMID: 19793000
27. Nguyen DT, Agarwal S, Graviss EA. Trends of tuberculosis meningitis and associated mortality in
Texas, 2010–2017, a large population-based analysis. PLoS One. 2019; 14: e0212729. https://doi.org/
10.1371/journal.pone.0212729 PMID: 30817805
28. Imran D, Hill PC, McKnight J, van Crevel R, TuberculousMeningitis International Research Consortium.
Establishing the cascade of care for patients with tuberculous meningitis. WellcomeOpen Res. 2019; 4:
177. https://doi.org/10.12688/wellcomeopenres.15515.2 PMID: 32118119
29. World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization;
2019.
PLOS GLOBAL PUBLIC HEALTH The global burden of tuberculous meningitis in adults
PLOSGlobal Public Health | https://doi.org/10.1371/journal.pgph.0000069 December 8, 2021 14 / 15
30. Horton KC, MacPherson P, Houben RMGJ,White RG, Corbett EL. Sex Differences in Tuberculosis
Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analy-
sis. PLoSMed. 2016; 13: e1002119. https://doi.org/10.1371/journal.pmed.1002119 PMID: 27598345
31. RajasinghamR, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of dis-
ease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17: 873–
881. https://doi.org/10.1016/S1473-3099(17)30243-8 PMID: 28483415
PLOS GLOBAL PUBLIC HEALTH The global burden of tuberculous meningitis in adults
PLOSGlobal Public Health | https://doi.org/10.1371/journal.pgph.0000069 December 8, 2021 15 / 15
